Survival Outcomes in Invasive Lobular Carcinoma Compared to Oestrogen Receptor-Positive Invasive Ductal Carcinoma

Cancers

Elinor Sawyer¹  Jasmine Timbres¹  Anca Mera²  Cheryl Gillett³  Charlotte Moss⁴  Mieke Van Hemelrijck⁴  Anna Haire⁴ 

[1] Breast Cancer Genetics, King’s College London, London SE1 9RT, UK;Guy’s & St. Thomas’ Hospital, London SE1 9RT, UK;KHP Cancer Biobank, King’s College London, London SE1 9RT, UK;Translational Oncology and Urology Research, King’s College London, London SE1 9RT, UK;

关键词: breast cancer;    lobular;    ductal;    chemotherapy;    survival;    cohort study;   

DOI  :  10.3390/cancers13123036

来源: DOAJ

【 摘 要 】

Invasive lobular breast cancer (ILC) accounts for 10–15% of breast cancers and has distinct characteristics compared with the more common invasive ductal carcinoma (IDC). Studies have shown that ILC may be less sensitive to chemotherapy than IDC, with lower rates of complete pathological response after neo-adjuvant chemotherapy, but it is not clear how this affects long-term survival. Patients at Guy’s and St Thomas’ NHS Foundation Trust between 1975 and 2016 diagnosed with ER+ IDC or ER+ ILC were eligible for inclusion. Kaplan–Meier plots and Cox proportional-hazards regression models were used for analysis. There was no difference in overall survival comparing ER+ ILC to ER+ IDC (OR: 0.94, 95% CI: 0.83, 1.04) with a median follow-up time of 8.3 years compared to 8.4 years in IDC. However, ER+HER2− ILC had worse survival compared to ER+HER2− IDC in those that received chemotherapy (OR: 1.46, 95% CI: 1.06, 2.01). Here, median follow-up time was 7.0 years in ILC compared to 8.1 years in IDC. These results indicate worse overall survival after chemotherapy (neo-adjuvant and adjuvant) in ILC compared to ER+HER2− IDC even when correcting for tumour grade, age, size, and nodal involvement, but validation is needed in a larger study population.

【 授权许可】

Unknown